Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04761107 · ClinicalTrials.gov registry record

Impact of COVID-19 on GU Disease

A clinical trial of COVID-19 Infection and Genitourinary Cancer, sponsored by Icahn School of Medicine at Mount Sinai.

Active
Registry status
15,240
Enrollment target
1
Study location

NCT04761107 is a study of COVID-19 Infection and Genitourinary Cancer that is active but no longer recruiting, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 15,240 participants, above the 2,426-participant average among 21 other COVID-19 Infection trials with a reported enrollment target (528% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04761107, a study of COVID-19 Infection and Genitourinary Cancer, is active but no longer recruiting, sponsored by Icahn School of Medicine at Mount Sinai.

ACTIVE NOT RECRUITING
Registry status
15,240 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to identify patients with GU disease with active or past COVID-19 infection. Participants will be asked to: * Complete an Online COVID-19 Questionnaire. * Disclose if the patient has or had Genitourinary cancer or benign urologic condition * Provide urine specimen for research * Provide 4 tablespoons of blood for testing blood for research. * Provide permission to access medical records, such as patient lab results, medical history, imaging reports, etc.

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 15,240 participants
Start Date 2021-02-18
Est. Completion 2026-02

What the Registry Record Tells You About NCT04761107

The ClinicalTrials.gov registry entry for NCT04761107 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 15,240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,426-participant average among 21 other COVID-19 Infection trials with a reported enrollment target (528% higher). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with COVID-19 Infection appearing as the primary indexed condition, and to 0 interventions.

NCT04761107 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT04761107 about?

NCT04761107 is a clinical study titled "Impact of COVID-19 on GU Disease". The purpose of this research study is to identify patients with GU disease with active or past COVID-19 infection. Participants will be asked to: * Complete an Online COVID-19 Questionnaire. * Disclose if the patient has or had Genitourinary cancer or benign urologic condition * Provide urine spec...

What is the current status of trial NCT04761107?

This trial is currently active not recruiting. The enrollment target is 15,240 participants. The study started on 2021-02-18. Estimated completion is 2026-02.

What conditions does trial NCT04761107 study?

This clinical trial studies the following conditions: COVID-19 Infection, Genitourinary Cancer, Benign Urologic Conditions.

Who is sponsoring clinical trial NCT04761107?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04761107 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19 Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.